Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

Expert Opinion on Biological Therapy

Volumn 11, Issue 4, 2011, Pages 473-487

  Roddie, Claire ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

allogeneic stem cell transplantation; DLI; graft versus host disease; relapse

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOREDUCTIVE SURGERY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SUICIDE GENE THERAPY; T CELL DEPLETION; TARGET CELL; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

ADULT; ANIMALS; CHILD; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HUMANS; LYMPHOCYTE TRANSFUSION; NEOPLASM, RESIDUAL; RECURRENCE; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79952590640     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.554811     Document Type: Review

References (134)

1. Aurer I, Gale RP. Are new conditioning regimens for transplants in acute myelogenous leukaemia better? Bone Marrow Transplantation 1991;7:255-61
2. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukaemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991;77:1660-5
3. Niederwieser D, Lange T, Cross M, et al. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006;19(4):825-38 (Pubitemid 44418026)
4. Slavin S. New strategies for bone marrow transplantation. Cur Opin Immunol 2000;12:542-51
5. Carella AM, Champlin R, Slavin S, et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000;25:345-50 (Pubitemid 30114026)
6. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008;14:246-55
7. Hegenbart U, Niederweser D, Sandmaier BM, et al. Treatment for acute myelogenous leukaemia by low-dose, total body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24:444-53 (Pubitemid 46630463)
8. Bensinger WI. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2006;20:1683-9 (Pubitemid 44574981)
9. Bagicalupo A. Results ofhematopoietic stem cell transplantation for hematologic malignancies. In: Hoffman R, Benz Jr EJ, Shattil SJ, et al. editors. Hematology: basic principles and practice. 4th edition. Churchill Livingstone, Edinburgh; 2004. p. 1713-25
10. Alyea EP, DeAngelo DJ, Moldrem J, et al. NCI First International Workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010; 16 (8): 1037-69
11. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-93 (Pubitemid 28482127)
12. Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16(11):1467-503
13. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62 (Pubitemid 20069191)
14. Collins RH, Rogers ZR, Bennett M, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992;10:391-5
15. Higano CS, Brixey M, Bryant EM, et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990;50:175-7 (Pubitemid 20221827)
16. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994;120:646-52 (Pubitemid 24106176)
17. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30
18. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986;1:53-66 (Pubitemid 17070365)
19. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999;96(15):8639-44 (Pubitemid 29354844)
20. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997;90(7):2529-34 (Pubitemid 27413460)
21. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062-7 (Pubitemid 41565901)
22. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23
23. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5
24. Cullis JO, Jiang YZ, Schwarer AP, et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992;79:1379-81
25. Bar BM, Schattenberg A, Mensink EJ, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993;11:513-19 (Pubitemid 23071050)
26. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-18 (Pubitemid 23304253)
27. Helg C, Roux E, Beris P, et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993;12:125-9 (Pubitemid 23243412)
28. Hertenstein B, Wiesneth M, Novotny J, et al. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993;56:1114-18
29. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6
30. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusion before the onset of hematologic relapse. Blood 1994;83:3377-83 (Pubitemid 24158488)
31. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8
32. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-50
33. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44 (Pubitemid 27074209)
34. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90(10):4206-11 (Pubitemid 27484078)
35. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000;26(7):769-74
36. Schaap N, Schattenberg A, Bar B, et al. Induction of graft-versus- leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by preemptive donor leukocyte infusions. Leukemia 2001;15(9):1339-46 (Pubitemid 32785303)
37. van der Griend R, Verdonck LF, Petersen EJ, et al. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23(2):195-7 (Pubitemid 29048225)
38. Verdonck LF, Petersen EJ, Lokhorst HM, et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998;22(11):1057-63 (Pubitemid 28554214)
39. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285(5426):412-15 (Pubitemid 29343964)
40. Mapara MY, Kim YM, Wang SP, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002;100(5):1903-9 (Pubitemid 34925172)
41. Bleakley M, Riddell SR Molecules and mechanisms of the graft-versus leukaemia effect. Nat Rev Cancer 2004;4(5):371-80
42. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-41 (Pubitemid 29153637)
43. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999;96:8639-44 (Pubitemid 29354844)
44. Hsieh MH, Korngold R. Differential use of FasL-and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 2000;96(3):1047-55 (Pubitemid 30616872)
45. Piccirillo CA, Shevach EM. Naturally-occurring CD4+ CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004;16:81-8 (Pubitemid 38234759)
46. Fehervari Z, Sakaguchi S. Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol 2004;16:203-8 (Pubitemid 38332029)
47. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9(9):1144-50 (Pubitemid 37173698)
48. Piccirillo CA, Shevach EM. Naturally-occurringCD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004;16:81-8 (Pubitemid 38234759)
49. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998;102:860-71 (Pubitemid 28387073)
50. Mackinnon S, Barnett L, Heller G, et al. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994;83:3409-16 (Pubitemid 24158492)
51. Kroger N, Bacher U, Bader P, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010;16(9):1187-211
52. Kroger N, Bacher U, Bader P, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 2010;16(10):1325-46
53. Sairafi D, Remberger M,Uhlin M, et al. "Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions". Biol Blood Marrow Transplant 2010;16(12):1728-37
54. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103(4):1548-56 (Pubitemid 38168677)
55. Kaeda J, O'shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006;107:4171-6 (Pubitemid 43726829)
56. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37 (Pubitemid 43990609)
57. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003;9:206-12
58. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-51
59. Mitterbauer G, Zimmer C, Fonatsch C, et al. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR Leukemia 1999;13:1519-24 (Pubitemid 29465613)
60. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88:2228-35 (Pubitemid 26307926)
61. Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leukemia Res 2005;29:961-6 (Pubitemid 40840724)
62. Kroger N, Zagrivnaja M, Schwartz S, et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006;34:688-94
63. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: A study on 593 infusions. Bone Marrow Transplant 2003;31:687-93 (Pubitemid 36553479)
64. Ocheni S, Iwanski GB, Schafhausen P, et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009;50(4):551-8
65. Cummins M, Cwynarski K, Marktel S, et al. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: A retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplant 2005;36:1065-9 (Pubitemid 43078134)
66. von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, et al. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia 2006;20(6):1040-6 (Pubitemid 43797295)
67. Posthuma EF, Marijt EW, Barge RM, et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 2004;10(3):204-12 (Pubitemid 38262883)
68. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-204 (Pubitemid 26086858)
69. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1009-15 (Pubitemid 41741565)
70. Chen J, Schmitt A, Chen B, et al. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 2007;56:849-61 (Pubitemid 46723580)
71. Gao H, Lee BN, Talpaz M, et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 2005;19:1905-11 (Pubitemid 41553998)
72. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007;25(31):4938-45 (Pubitemid 350225492)
73. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675-87
74. Fielding AK, Richards SM, Chopra R, et al. Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109(3):944-50
75. Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95(4):1214-21 (Pubitemid 30099829)
76. Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005;36(5):437-41 (Pubitemid 43115032)
77. Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010;28(23):3695-700
78. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(1):50-8 (Pubitemid 350286737)
79. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27(3):426-32
80. Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008;19(11):1935-40
81. Cook G, Smith GM, Kirkland K, et al. Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT). Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): A study of the British society for blood and marrow transplantation. Biol Blood Marrow Transplant 2010;16(10):1419-27
82. Selenko N, Majdic O, Jager U, et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002;22(3):124-30 (Pubitemid 34596935)
83. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14(2):572-8 (Pubitemid 26051023)
84. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol 2008;143(4):468-80
85. Peggs KS, Sureda A, Qian W, et al. UK and Spanish Collaborative Groups. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007;139(1):70-80 (Pubitemid 47389932)
86. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(3):455-62 (Pubitemid 351171699)
87. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients following T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; In press
88. Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008;14(11):1288-97
89. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106(13):4389-96 (Pubitemid 41775953)
90. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR Blood 2004;104(8):2600-2 (Pubitemid 39331866)
91. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100(9):3108-14 (Pubitemid 35217056)
92. Ritgen M, Bottcher S, Stilgenbauer S, et al.; German CLL Study Group. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008;22(7):1377-86 (Pubitemid 352006082)
93. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107(4):1325-31 (Pubitemid 43242365)
94. Buhmann R, Simoes B, Stanglmaier M, et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009;43(5):383-97
95. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37(12):1135-41 (Pubitemid 43871524)
96. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103(11):4362-4 (Pubitemid 38685385)
97. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9(4):257-65 (Pubitemid 40045612)
98. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004;101(21):8120-5 (Pubitemid 38698064)
99. Erratum in: Proc Natl Acad Sci USA. 2004;101(34):12777
100. Lioznov M, El-Cheikh J Jr, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010;45(2):349-53
101. Levine JE, Barrett AJ, Zhang MJ, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008;42(3):201-5
102. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340-7 (Pubitemid 30056423)
103. Yoshimi A, Bader P, Matthes-Martin S, et al. European Working Group of MDS in Childhood (EWOG-MDS). Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005;19:971-7 (Pubitemid 40862007)
104. Ladon D, Pieczonka A, Jolkowska J, et al. Molecular follow up of donor lymphocyte infusion in CML children after allogeneic bone marrow transplantation. Appl Genet 2001;42:547-52 (Pubitemid 33669673)
105. Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 1999;13:2079-86
106. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavourable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004;22:1696-705 (Pubitemid 41079809)
107. Hoelle W, Beck JF, Dueckers G, et al. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anaemia. Bone Marrow Transplant 2004;33:219-23 (Pubitemid 38180936)
108. Frugnoli I, Cappelli B, Chiesa R, et al. Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia. Bone Marrow Transplant 2010;45(6):1047-51
109. Rezvani K, Rahemtulla A, Cummins M, et al. Response of CML to donor lymphocyte infusions (DLI): factors influencing the effective cell dose and implications for the definition of refractoriness. Blood 2000;96(S1):195
110. Bertz H, Burger JA, Kunzmann R, et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997;11(2):281-3 (Pubitemid 27085174)
111. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100(9):3108-14 (Pubitemid 35217056)
112. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986;68:770-3 (Pubitemid 16008184)
113. Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007;20(2):311-27 (Pubitemid 46585972)
114. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71 (Pubitemid 30017226)
115. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-83 (Pubitemid 24158488)
116. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia. Science 1997;276(5319):1719-24 (Pubitemid 27421983)
117. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998;9(15):2243-51 (Pubitemid 28498010)
118. Deschamps M, Mercier-Lethondal P, Certoux JM, et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 2007;110:3842-52 (Pubitemid 350248439)
119. Berger C, Flowers ME, Warren EH, et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107:2294-302 (Pubitemid 43345547)
120. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus host disease. Blood 2001;97(5):1249-57 (Pubitemid 32183746)
121. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54 (Pubitemid 40720769)
122. Hartwig UF, Nonn M, Khan S, et al. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008;14:99-109 (Pubitemid 350286744)
123. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007;109:365-73 (Pubitemid 46053079)
124. Kamiryo Y, Eto M, Yamada H, et al. Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 2009;69(12):5151-8
125. Champlin R, Jansen J, Ho W, et al. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991;23:1695-6
126. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-43
127. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and effcacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80 (Pubitemid 28225734)
128. Orti G, Lowdell M, Fielding A, et al. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Transplantation 2009;88(11):1312-18
129. Aqui NA, June CH. Post-transplant adoptive T-cell immunotherapy. Best Pract Res Clin Haematol 2008;21(3):503-19
130. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9 (Pubitemid 44547756)
131. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-5 (Pubitemid 34044918)
132. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15 (Pubitemid 44703776)
133. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:20-2
134. Pule MA, Savoldo B, Myers GD, et al. Virus-specificTcells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70